Chronic myeloid leukemia (CML) patients who do not achieve landmark responses following treatment with imatinib mesylate (IM) are considered IM-resistant. Although IM-resistance can be due to BCR-ABL kinase domain (KD) mutations, many IM-resistant patients do not have detectable BCR-ABL KD mutations. MicroRNAs (miRNAs) are short non-coding RNAs that control gene expression. To investigate the role of miRNAs in IM-resistance, we recruited 8 chronic phase CML patients with IM-resistance who tested negative for BCR-ABL KD mutations and 2 healthy normal controls. Using miRNA sequencing, we identified 54 differentially expressed miRNAs; 43 of them downregulated. The 3 most differentially downregulated miRNAs were miR-146a-5p, miR-99b-5p and miR-151a-5p. Using real-time quantitative reverse transcriptase-polymerase chain reaction, the expression patterns of the 3 miRNAs were validated on the same cohort of 8 patients in addition to 3 other IM-resistant CML patients. In-silico analysis showed that the predicted gene targets are ATRIP, ATR, WDR48, RAD51C and FANCA genes which are involved in the Fanconi Anemia/BRCA pathway. This pathway regulates DNA damage response (DDR) and influences disease response to chemotherapy. Thus it is conceivable that DDR constitutes a key component in IM-resistance. Further research is needed to elucidate miRNA modulation of the predicted gene targets.

1. N. Shah, C. Sawyers, Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias, Oncogene 22 (47) (2003) 7389–7395.
2. R. Nimmanapalli, L. Fuino, C. Stobaugh, V. Richon, K. Bhalla, Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells, Blood 101 (8) (2003) 3236–3239.
3. M.J. Bueno, Pérez de Castro I, Gómez de Cedrón M, J. Santos, G.A. Calin, J.C. Cigudosa, et al., Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression, Med. Clin. (Barc) 13 (2008) 496–506.
4. P. Machová, T. Lopotová, H. Klamová, P. Burda, M. Trněný, T. Stopka, et al., Expression patterns of microRNAs associated with CML phases and their disease related targets, Mol. Cancer 10 (2011) 41.
5. C. Chakraborty, A. Sharma, B. Patra, M. Bhattacharya, G. Sharma, S. Lee, et al., MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia, Oncotarget 10 (2016).
6. J.E. San, J. Román-Gómez, A. Jiménez-Velasco, L. Garate, V. Martin, L. Cordeu, et al., MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations, Mol. Cancer 8 (2009) 69.
7. S. Di, G. Mirone, S. Perna, G. Marfe, The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review), Oncol. Rep. 35 (2) (2016) 614–624.
8. S. Flamant, W. Ritchie, J. Guilhot, J. Holst, M.L. Bonnet, J.C. Chomel, et al., MicroRNA response to imatinib mesylate in patients with chronic myeloid leukemia, Haematologica 95 (8) (2010) 1325–1333.
9. S. Bhutra, D. Lenkala, B. LaCroix, M. Ye, Huang R. Identifying, Validating a combined mRNA and MicroRNA signature in response to imatinib treatment in a chronic myeloid Leukemia cell line, PLoS One 9 (12) (2014) 10.
10. National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2015). http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed August 13, 2015
11. M.H. Elias, A.A. Baba, A. Husin, A.D. Abdullah, R. Hassan, G.A. Sim, et al., Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients, Med. Clin. (Barc). 4 (2012) (e23).
12. S. Motameny, S. Wolters, P. Nürnberg, B. Schumacher, Next generation sequencing of miRNAs −strategies, resources and methods, Genes (Basel). 1 (1) (2010) 70–84.
13. Command-line tools for processing biological sequencing data [Internet]. [updated 2011; cited Available from: http://code.google.com/p/ea-utils
14. S. Burge, J. Daub, R. Eberhardt, J. Tate, L. Barquist, E. Nawrocki, et al., Rfam 11.0: 10 years of RNA families, Nucleic Acids Res. 41 (2013) D226–D232 (Database issue).
15. P.P. Chan, T.M. Lowe, GtRNAdb: a database of transfer RNA genes detected in genomic sequence, Nucleic Acids Res. 37 (2009) D93–D97 (Database issue).
16. B. Langmead, C. Trapnell, M. Pop, Salzberg S. Ultrafast, memory-efficient alignment of short DNA sequences to the human genome, Genome Biol. 10 (3) (2009) 10.
17. A. Mortazavi, B. Williams, K. McCue, L. Schaeffer, B. Wold, Mapping and quantifying mammalian transcriptomes by RNA-Seq, Nat. Methods 5 (7) (2008) 621–628.
18. I. Vlachos, N. Kostoulas, T. Vergoulis, G. Georgakilas, M. Reczko, M. Maragkakis, et al., DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways, Nucleic Acids Res. 40 (Web Server issue) (2012) W498–W504.
19. M. Kanehisa, S. Goto, KEGG: kyoto encyclopedia of genes and genomes, Nucleic Acids Res. 28 (1) (2000) 27–30.
20. D. Bixby, M. Talpaz, Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance, Hematol. Am. Soc. Hematol. Educ. Program 46 (2009) 1–47 (6).
21. P.K. Bhamidipati, H. Kantarjian, J. Cortes, A.M. Cornelison, E. Jabbour, Management of imatinib-resistant patients with chronic myeloid leukemia, Therapeut. Adv. Hematol. 4 (2) (2013) 103–117.
22. M. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. Rao, et al., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science 293 (5531) (2001) 876–880.
23. A. Hochhaus, R. La, Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance, Leukemia 18 (8) (2004) 1321–1331.
24. S. Soverini, A. Hochhaus, F. Nicolini, F. Gruber, T. Lange, G. Saglio, et al., BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet, Blood 118 (5) (2011) 1208–1215.
25. S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M. Bernard, et al., Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood 109 (8) (2007) 3496–3499.
26. A. Sekulić, C. Hudson, J. Homme, P. Yin, D. Otterness, L. Karnitz, et al., A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells, Cancer Res. 60 (13) (2000) 3504–3513.
27. Y. Liu, W. Zheng, Y. Song, W. Ma, H. Yin, Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis, PLoS One 8 (7) (2013) 10.
28. K. Ohyashiki, T. Umezu, S. Katagiri, C. Kobayashi, K. Azuma, T. Tauchi, et al., Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib, Int. J. Mol. Sci. 17 (4) (2016) 570.
29. H. Lin, K. Rothe, J. Ruschmann, O. Petriv, K. O'Neill, D.J. Knapp, et al., Identification of new microRNA biomarkers and candidate target genes in primitive CML cells using global comparative RNA analyses, Blood 124 (2014) 3133.
30. O. Rokah, G. Granot, A. Ovcharenko, S. Modai, M. Pasmanik-Chor, A. Toren, et al., Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells, PLoS One 7 (4) (2012) 10.
31. G. Moldovan, A. D'Andrea, How the fanconi anemia pathway guards the genome, Annu. Rev. Genet. 43 (2009) 223–249.
32. S. Nakashima, S. Kobayashi, H. Nagano, A. Tomokuni, Y. Tomimaru, T. Asaoka, et al., BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer, Cancer Sci. 106 (5) (2015) 584–591.
33. S. Fagerlie, T. Koretsky, B. Torok-Storb, G. Bagby, Impaired type I IFN-induced Jak/ STAT signaling in FA-C cells and abnormal CD4+ Th cell subsets in Fancc-/- mice, J. Immunol. 173 (6) (2004) 3863–3870.
34. Y. Kee, J. Kim, A. D'Andrea, Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis, Genes Dev. 23 (5) (2009) 555–560.
35. N. Collins, J. Wilson, T. Bush, A. Thomashevski, K. Roberts, N. Jones, et al., ATRdependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function, Blood 113 (10) (2009) 2181–2190.
36. D. Cortez, S. Guntuku, J. Qin, S.A. Elledge, ATR and ATRIP: partners in checkpoint signaling, Science 294 (5547) (2001) 1713–1716.
37. F. Wei, J. Yan, D. Tang, Extracellular signal-regulated kinases modulate DNA damage response − a contributing factor to using MEK inhibitors in cancer therapy, Curr. Med. Chem. 18 (35) (2011) 5476–5482.
38. J. Li, Y. Dang, J. Gao, Y. Li, J. Zou, L. Shen, et al., PI3 K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs), Med. Oncol. 32 (4) (2015) 111.
39. A. Burchert, Y. Wang, D. Cai, B. von, P. Paschka, S. Müller-Brüsselbach, et al., Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development, Leukemia 19 (10) (2005) 1774–1782.
40. F. Vaz, H. Hanenberg, B. Schuster, K. Barker, C. Wiek, V. Erven, et al., Mutation of the RAD51C gene in a Fanconi anemia-like disorder, Nat. Genet. 42 (5) (2010) 406–409.
41. A. Meindl, N. Ditsch, K. Kast, K. Rhiem, R. Schmutzler, Hereditary breast and ovarian cancer: new genes, new treatments, new concepts, Dtsch Arztebl Int 108 (19) (2011) 323–330.
42. A. Slupianek, G. Hoser, I. Majsterek, A. Bronisz, M. Malecki, J. Blasiak, et al., Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis, Mol. Cell. Biol. 22 (12) (2002) 4189–4201.
43. T. Skorski, BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability, Oncogene 21 (56) (2002) 8591–8604.
44. S. Collis, A. Tighe, S. Scott, S. Roberts, J. Hendry, G. Margison, et al., Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells, Nucleic Acids Res. 29 (7) (2001) 1534–1538.
45. M. Cohn, Y. Kee, W. Haas, S. Gygi, A. D'Andrea, UAF1 is a subunit of multiple deubiquitinating enzyme complexes, J. Biol. Chem. 284 (8) (2009) 5343–5351.
46. M. Cohn, P. Kowal, K. Yang, W. Haas, T. Huang, S. Gygi, et al., A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway, Mol. Cell 28 (5) (2007) 786–797.
47. G. Tan, E. Chan, A. Molnar, R. Sarkar, D. Alexieva, I. Isa, et al., 5' isomiR variation is of functional and evolutionary importance, Nucleic Acids Research 2014 42 (14) (2014) 9424–9435.
48. C. Neilsen, G. Goodall, C. Bracken, IsomiRs–the overlooked repertoire in the dynamic microRNAome, Trends Genet. 28 (11) (2012) 544–549.